Literature DB >> 26298279

Important abnormalities of bone mineral metabolism are present in patients with coronary artery disease with a mild decrease of the estimated glomerular filtration rate.

Emilio González-Parra1, Álvaro Aceña2, Óscar Lorenzo3, Nieves Tarín4, María Luisa González-Casaus5, Carmen Cristóbal6, Ana Huelmos7, Ignacio Mahíllo-Fernández8, Ana María Pello2, Rocío Carda2, Ignacio Hernández-González2, Joaquín Alonso6, Fernando Rodríguez-Artalejo9, Lorenzo López-Bescós10, Alberto Ortiz1, Jesús Egido1,11, José Tuñón12.   

Abstract

Chronic kidney disease (CKD)-mineral and bone disorder (MBD) is characterized by increased circulating levels of parathormone (PTH) and fibroblast growth factor 23 (FGF23), bone disease, and vascular calcification, and is associated with adverse outcomes. We studied the prevalence of mineral metabolism disorders, and the potential relationship between decreased estimated glomerular filtration rate (eGFR) and CKD-MBD in coronary artery disease patients in a cross-sectional study of 704 outpatients 7.5 ± 3.0 months after an acute coronary syndrome. The mean eGFR (CKD Epidemiology Collaboration formula) was 75.8 ± 19.1 ml/min/1.73 m(2). Our patients showed lower calcidiol plasma levels than a healthy cohort from the same geographical area. In the case of men, this finding was present despite similar creatinine levels in both groups and older age of the healthy subjects. Most patients (75.6 %) had an eGFR below 90 ml/min/1.73 m(2) (eGFR categories G2-G5), with 55.3 % of patients exhibiting values of 60-89 ml/min/1.73 m(2) (G2). PTH (r = -0.3329, p < 0.0001) and FGF23 (r = -0.3641, p < 0.0001) levels inversely correlated with eGFR, whereas calcidiol levels and serum phosphate levels did not. Overall, PTH levels were above normal in 34.9 % of patients. This proportion increased from 19.4 % in G1 category patients, to 33.7 % in G2 category patients and 56.6 % in G3-G5 category patients (p < 0.001). In multivariate analysis, eGFR and calcidiol levels were the main independent determinants of serum PTH. The mean FGF23 levels were 69.9 (54.6-96.2) relative units (RU)/ml, and 33.2 % of patients had FGF23 levels above 85.5 RU/ml (18.4 % in G1 category patients, 30.0 % in G2 category patients, and 59.2 % in G3-G5 category patients; p < 0.001). In multivariate analysis, eGFR was the main predictor of FGF23 levels. Increased phosphate levels were present in 0.7 % of the whole sample: 0 % in G1 category patients, 0.3 % in G2 category patients, and 2.8 % in G3-G5 category patients (p = 0.011). Almost 90 % of patients had calcidiol insufficiency without significant differences among the different degrees of eGFR. In conclusion, in patients with coronary artery disease there is a large prevalence of increased FGF23 and PTH levels. These findings have an independent relationship with decreased eGFR, and are evident at an eGFR of 60-89 ml/min/1.73 m(2). Then, mild decreases in eGFR must be taken in consideration by the clinician because they are associated with progressive abnormalities of mineral metabolism.

Entities:  

Keywords:  Coronary artery disease; Fibroblast growth factor 23; Glomerular filtration rate; Parathormone; Vitamin D

Mesh:

Substances:

Year:  2015        PMID: 26298279     DOI: 10.1007/s00774-015-0706-y

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  53 in total

1.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

Review 2.  Defective renal maintenance of the vitamin D endocrine system impairs vitamin D renoprotection: a downward spiral in kidney disease.

Authors:  Adriana S Dusso; Masanori Tokumoto
Journal:  Kidney Int       Date:  2011-01-26       Impact factor: 10.612

3.  Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: dependent or independent risk factors?

Authors:  Jeffrey L Anderson; Ryan C Vanwoerkom; Benjamin D Horne; Tami L Bair; Heidi T May; Donald L Lappé; Joseph B Muhlestein
Journal:  Am Heart J       Date:  2011-08       Impact factor: 4.749

Review 4.  Phosphate: a stealthier killer than previously thought?

Authors:  Emilio Gonzalez-Parra; Jose Tuñón; Jesus Egido; Alberto Ortiz
Journal:  Cardiovasc Pathol       Date:  2012-03-16       Impact factor: 2.185

5.  A comparison of the CKD-EPI, MDRD-4, and Cockcroft-Gault equations to assess renal function in predicting all-cause mortality in acute coronary syndrome patients.

Authors:  Emad Abu-Assi; Pamela Lear; Pilar Cabanas-Grandío; Mar Rodríguez-Girondo; Sergio Raposeiras-Roubin; Eva Pereira-López; Santiago Gestal Romaní; Carlos Peña- Gil; José María García-Acuña; José Ramón González-Juanatey
Journal:  Int J Cardiol       Date:  2012-12-04       Impact factor: 4.164

Review 6.  The emerging role of Klotho in clinical nephrology.

Authors:  Ming Chang Hu; Makoto Kuro-o; Orson W Moe
Journal:  Nephrol Dial Transplant       Date:  2012-07       Impact factor: 5.992

Review 7.  Adynamic bone disease: from bone to vessels in chronic kidney disease.

Authors:  Jordi Bover; Pablo Ureña; Vincent Brandenburg; David Goldsmith; César Ruiz; Iara DaSilva; Ricardo J Bosch
Journal:  Semin Nephrol       Date:  2014-11       Impact factor: 5.299

8.  Fibroblast growth factor 23 accelerates phosphate-induced vascular calcification in the absence of Klotho deficiency.

Authors:  Rika Jimbo; Fumiko Kawakami-Mori; Shengyu Mu; Daigoro Hirohama; Bohumil Majtan; Yuichiro Shimizu; Yutaka Yatomi; Seiji Fukumoto; Toshiro Fujita; Tatsuo Shimosawa
Journal:  Kidney Int       Date:  2013-10-02       Impact factor: 10.612

9.  Calcium deficiency reduces circulating levels of FGF23.

Authors:  María E Rodriguez-Ortiz; Ignacio Lopez; Juan R Muñoz-Castañeda; Julio M Martinez-Moreno; Alan Peralta Ramírez; Carmen Pineda; Antonio Canalejo; Philippe Jaeger; Escolastico Aguilera-Tejero; Mariano Rodriguez; Arnold Felsenfeld; Yolanda Almaden
Journal:  J Am Soc Nephrol       Date:  2012-05-10       Impact factor: 10.121

10.  Parathyroid-specific deletion of Klotho unravels a novel calcineurin-dependent FGF23 signaling pathway that regulates PTH secretion.

Authors:  Hannes Olauson; Karolina Lindberg; Risul Amin; Tadatoshi Sato; Ting Jia; Regina Goetz; Moosa Mohammadi; Göran Andersson; Beate Lanske; Tobias E Larsson
Journal:  PLoS Genet       Date:  2013-12-12       Impact factor: 5.917

View more
  3 in total

Review 1.  Nutrients Turned into Toxins: Microbiota Modulation of Nutrient Properties in Chronic Kidney Disease.

Authors:  Raul Fernandez-Prado; Raquel Esteras; Maria Vanessa Perez-Gomez; Carolina Gracia-Iguacel; Emilio Gonzalez-Parra; Ana B Sanz; Alberto Ortiz; Maria Dolores Sanchez-Niño
Journal:  Nutrients       Date:  2017-05-12       Impact factor: 5.717

2.  Design and rationale of a multicentre, randomised, double-blind, placebo-controlled clinical trial to evaluate the effect of vitamin D on ventricular remodelling in patients with anterior myocardial infarction: the VITamin D in Acute Myocardial Infarction (VITDAMI) trial.

Authors:  José Tuñón; Ignacio González-Hernández; Lucía Llanos-Jiménez; Joaquín Alonso-Martín; Juan M Escudier-Villa; Nieves Tarín; Carmen Cristóbal; Petra Sanz; Ana M Pello; Álvaro Aceña; Rocío Carda; Miguel Orejas; Marta Tomás; Paula Beltrán; Marta Calero Rueda; Esther Marcos; José María Serrano-Antolín; Carlos Gutiérrez-Landaluce; Rosa Jiménez; Jorge Cabezudo; Alejandro Curcio; Germán Peces-Barba; Emilio González-Parra; Raquel Muñoz-Siscart; María Luisa González-Casaus; Antonio Lorenzo; Ana Huelmos; Javier Goicolea; Borja Ibáñez; Gonzalo Hernández; Luis M Alonso-Pulpón; Jerónimo Farré; Óscar Lorenzo; Ignacio Mahíllo-Fernández; Jesús Egido
Journal:  BMJ Open       Date:  2016-08-05       Impact factor: 2.692

3.  A risk scoring system for the decreased glomerular filtration rate in Chinese general population.

Authors:  Yan Gu; Min Chen; Bei Zhu; Xiaohua Pei; Zhenzhu Yong; Xiaona Li; Qun Zhang; Weihong Zhao
Journal:  J Clin Lab Anal       Date:  2019-12-22       Impact factor: 2.352

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.